Revised July 2009

Southern University - Baton Rouge (SUBR)

Institution Review Board (IRB)
for the Protection of Human Subjects

Checklist for Reviewing Research Permission or Consent Form

Directions: Use this checklist to ensure that the basic and additional consent elements are included in the research permission or consent form. Write Yes or No in the left column cells.

Yes or No	Basic and Additional Consent Elements
	1 - Provided title of research.
	2 - Delineated name(s), address(es), telephone number(s), and e-mail address(es) of principal investigator(s)/researcher(s).
	3 - Stated purpose of the research study and described procedures to be used.
	4 - Described possible risks or discomforts.
	5 - Described possible benefits to subjects/participants or others.
	6 - Disclosed available alternative courses of treatment(s) or procedure(s).
	7 - Described available medical treatment for adverse events or experiences (greater than minimal risk).
	8 - Described the extent of confidentiality and anonymity for subjects/participants.
	9 - Whom to contact about the research—Include the following statements: a) For additional information about this research study contact –name(s), address(es), and telephone number(s) of principal investigator(s). b) If you have questions or concerns about your rights as a participant in this research study or to report a research-related injury, contact Dr. Patrick Carriere, Ph.D., Chairperson, Institutional Research Oversight Committee, P.O. Box 11241 Southern University -Baton Rouge, Baton Rouge, LA 70813-1241, (Voice) 225-771-5290 Ext 183; (Facsimile) 225-771-5721 ; Email carriere@engr.subr.edu

	10 - Stated the following: Participation is voluntary; refusal to participate involves no penalty or loss of benefits that the subject is otherwise entitled; Subjects may discontinue participation without penalty or loss of benefits that the subjects are otherwise entitled.
	11 - Stated the procedure may involve currently unforeseeable risks to the subjects or fetuses, if the subjects become pregnant.
	12 - Described anticipated circumstances under which subject participation may be terminated by the principal investigator(s) without regard to the subject's consent.
	13 - Disclosed additional cost to subjects as a result of participation in the study.
	14 - Described circumstances under which subjects can withdraw from the study and procedures for orderly termination.
	15 – Stated that significant new findings that may relate to subjects' willingness to continue participation in the study will be disclosed to the subjects.
	16 - Stated the possible number of subjects involved in the study.
	17- Stated subjects will receive a signed copy of the consent form.

Comments: